![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Hepatitis C Treatment Outcomes and Predictors of Response in Treatment-naive Patients Treated with Peginterferon Alfa/Ribavirin in Real-world Italian Clinics Compared with Other Countries: PROPHESYS Sub-analysis
|
|
|
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
A. Ascione,1 S. Bruno,2 C. Coppola,3 A. Mangia,4 A. Orlandini,5 M. Schmitz,6 B. Deodato,7 M. Puoti8; on behalf of the PROPHESYS 2 study group
1Centre for Liver Disease, Fatebenefratelli Hospital, Naples, Italy; 2Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milan, Italy; 3Unita Operativa di Epatologia ed Ecografia Interventistica Ospedale Gragnano, Naples, Italy; 4IRCCS Hospital 'Casa Sollievo della Sofferenza', San Giovanni Rotondo, Italy; 5Azienda Ospedaliero-Universitaria di Parma, Parma, Italy; 6IST GmbH, Mannheim, Germany; 7Roche SpA, Monza, Italy; 8University of Brescia, Brescia, Italy
![EASL1.gif](../images/051113/051113-8/EASL1.gif)
![EASL2.gif](../images/051113/051113-8/EASL2.gif)
![EASL3.gif](../images/051113/051113-8/EASL3.gif)
![EASL4.gif](../images/051113/051113-8/EASL4.gif)
![EASL5.gif](../images/051113/051113-8/EASL5.gif)
![EASL6.gif](../images/051113/051113-8/EASL6.gif)
![EASL7.gif](../images/051113/051113-8/EASL7.gif)
![EASL8.gif](../images/051113/051113-8/EASL8.gif)
![EASL9.gif](../images/051113/051113-8/EASL9.gif)
![EASL10.gif](../images/051113/051113-8/EASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|